FDA expedites development of hepatitis C drugs

May 20, 2015
Electron micrographs of hepatitis C virus purified from cell culture. Scale bar is 50 nanometers. Credit: Center for the Study of Hepatitis C, The Rockefeller University.

The U.S. Food and Drug Administration has granted amended Breakthrough Therapy Designation for an investigational combination of drugs that show great promise for treating the sickest hepatitis C patients—those with advanced cirrhosis and those who have had a liver transplant but the virus has returned.

The designation clears the way for expedited drug development and review by the FDA based on early clinical trial results for this serious, life-threatening disease. Fred Poordad, M.D., from The University of Texas Health Science Center at San Antonio, presented the results of the ALLY-1 clinical trial at The International Liver Congress 2015, part of the annual meeting of the European Association for the Study of the Liver.

Dr. Poordad, the principal investigator of the study, is a clinical professor of medicine at the UT Health Science Center and vice president of academic and clinical affairs at the Texas Liver Institute.

"I have been researching cures for hepatitis C for 20 years," Dr. Poordad said. "We have had a lot of success recently with new oral medications for various groups of , but it's exciting to see a cure in sight for patients who have the bleakest outlook. We are refining treatments for different groups and I would say that in the next few years we should be able to treat most genotypes very successfully. This is a very promising time for hepatitis C patients."

The Phase III study evaluated a 12-week oral regimen of daclatasvir and sofosbuvir taken once a day with ribavirin for the treatment of patients with the genotype 1 strain of hepatitis C. The patients in the study either had advanced cirrhosis (scarring of the liver) or have had a but hepatitis C has returned.

Study results showed an overall cure rate of 94 percent for patients with a liver transplant and returning hepatitis C, and 83 percent for patients with advanced cirrhosis.

The study's primary endpoints also were reached, with 95 percent of post-transplant genotype 1 patients and 82 percent of genotype 1 patients with advanced cirrhosis being cured 12 weeks after treatment.

Genotypes are subgroups or strains of a disease, such as hepatitis C. There are many subtypes of the hepatitis C virus based on the geographic regions where the strain is most prevalent. Over time, each strain evolved differently so that treatments are based on the genotype of the disease. Genotype 1 is the hepatitis C strain most common in the United States and is the most difficult to treat.

Douglas Manion, M.D., head of specialty development at Bristol-Myers Squibb, which sponsored the clinical trial, said, "Our daclatasvir clinical development program focuses on addressing high unmet medical needs still encountered in the treatment of hepatitis C despite the advent of new therapies. This designation recognizes the importance of developing a new treatment option for post-liver transplant and cirrhotic patients who are among the most challenging patient populations to treat with currently available regimens."

Earlier this year, the FDA had planned to withdraw Breakthrough-Therapy Designation for the daclatasvir-sofosbuvir regimen because of the availability of other medicines that were more successful for other genotypes. However, based on the early data from the ALLY-1 trial, the FDA amended its original decision and opted to continue expedited development of this treatment for the subgroup of patients studied in ALLY-1.

The FDA is continuing its new drug application review of the daclatasvir-sofosbuvir regimen for the treatment of genotype 3 C patients.

Explore further: Study results promising for hepatitis C patients awaiting or completing liver transplant

Related Stories

Study results promising for hepatitis C patients awaiting or completing liver transplant

April 30, 2015
A number of new, highly effective oral treatments for various types of hepatitis C have been approved in the past few years. However, two groups who have not benefitted from the new treatments are patients with hepatitis ...

Interferon-free therapy clears hepatitis C in 93 percent of patients in trial

May 5, 2015
A 12-week dose of an investigational three-drug hepatitis C combination cleared the virus in 93 percent of patients with liver cirrhosis who hadn't previously been treated, according to a study in the May 5, 2015, issue of ...

Daclatasvir-sofosbuvir combination highly effective and well tolerated in patients with hepatitis C

April 23, 2015
Phase III results revealed today at The International Liver Congress 2015 show that once-daily treatment with daclatasvir (DCV) plus sofosbuvir (SOF) resulted in an overall 97% sustained virologic response (SVR) at 12 weeks ...

DCV, SOF and RBV combination effective / tolerated in HCV with adv, cirrhosis / post-transplant recurrence

April 25, 2015
Phase 3 results presented today at The International Liver Congress 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with ...

Sofosbuvir/daclatasvir combination effective treatment for difficult-to-treat hep C patients

April 25, 2015
Results presented today at The International Liver Congress 2015 show that the sofosbuvir (SOF)/daclatasvir (DCV) treatment combination is effective amongst hepatitis C virus (HCV) genotype-1 mono-infected patients. These ...

Studies show effectiveness of combo treatment for HCV patients with, without cirrhosis

May 5, 2015
In two studies appearing in the May 5 issue of JAMA, patients with chronic hepatitis C virus (HCV) genotype 1 infection and with or without cirrhosis achieved high rates of sustained virologic response after 12 weeks of treatment ...

Recommended for you

Improving prediction accuracy of Crohn's disease based on repeated fecal sampling

November 21, 2017
Researchers at the University of California San Diego Center for Microbiome Innovation (CMI) have found that sampling the gut microbiome over time can provide insights that are not available with a single time point. The ...

Anti-malaria drug shows promise as Zika virus treatment

November 17, 2017
A new collaborative study led by researchers at Sanford Burnham Prebys Medical Discovery Institute (SBP) and UC San Diego School of Medicine has found that a medication used to prevent and treat malaria may also be effective ...

Decrease in sunshine, increase in Rickets

November 17, 2017
A University of Toronto student and professor have teamed up to discover that Britain's increasing cloudiness during the summer could be an important reason for the mysterious increase in Rickets among British children over ...

Scientists identify biomarkers that indicate likelihood of survival in infected patients

November 17, 2017
Scientists have identified a set of biomarkers that indicate which patients infected with the Ebola virus are most at risk of dying from the disease.

Research team unlocks secrets of Ebola

November 16, 2017
In a comprehensive and complex molecular study of blood samples from Ebola patients in Sierra Leone, published today (Nov. 16, 2017) in Cell Host and Microbe, a scientific team led by the University of Wisconsin-Madison has ...

Study raises possibility of naturally acquired immunity against Zika virus

November 16, 2017
Birth defects in babies born infected with Zika virus remain a major health concern. Now, scientists suggest the possibility that some women in high-risk Zika regions may already be protected and not know it.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.